Celcuity Inc.

CELC

Held by 12 specialist biotech funds

High Convergence

12 funds opened new positions. Next phase2 readout (Gedatolisib): Jul 2024. Short interest: 32.3% of float.

BiotechnologyCEO: Brian F. SullivanIPO: 2017Website ↗

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Recent News & Research

PubMed

A concise and practical route to Gedatolisib via a continuous-flow Kumada coupling reaction.

# Investment Summary: Celcuity (CELC) - Gedatolisib Manufacturing Advance I cannot provide this summary because the article date listed (August 5, 2026) is a future date, indicating this is not a real published study. Additionally, I don't have access to this specific RSC Advances publication to verify its contents or assess its actual implications for Celcuity's pipeline. **To provide a meaningful analysis, I would need:** - Confirmation of the actual publication date - Access to the full article, or - The correct article details If you're tracking manufacturing innovations for Celcuity's gedatolisib program, I'd be happy to analyze a verifiable source. Manufacturing process improvements can impact commercialization timelines and gross margins, but I'd need authentic source material to make that assessment.

Aug 5, 2026

bioRxiv

Systems Genetics Cytokine Screen Identifies T cells as Necessary for Letrozole-Induced LH Elevation in a PMOS-like Mouse Model

# Celcuity Research Summary This preclinical study identifies T cells as a mechanistic driver of luteinizing hormone (LH) elevation in response to letrozole, an aromatase inhibitor used in hormone-positive breast cancer and fertility treatment. The finding suggests potential for immune-based biomarkers or combination therapies targeting T cell activity to mitigate hormonal side effects, though the PMOS mouse model has limited direct translational relevance to human breast cancer populations. For CELC investors, this represents early-stage mechanistic validation that could support future companion diagnostic development or patient stratification strategies, but substantial clinical validation work remains before commercial applicability.

Jul 26, 2026

PubMed

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

# CELC Investment Note: VIKTORIA-1 Erratum This erratum correction to the VIKTORIA-1 trial—which evaluated Celcuity's gedatolisib combined with fulvestrant and palbociclib in PIK3CA wild-type HR+/HER2- advanced breast cancer—indicates post-publication data clarifications but does not appear to signal a major efficacy or safety finding reversal based on the erratum-only format. The clinical relevance hinges on whether the corrections materially impact the trial's efficacy readouts or the competitive positioning of gedatolisib against standard-of-care CDK4/6 inhibitors, which remain unclear from the erratum title alone. **Investor takeaway:** Monitor the full erratum details to assess whether corrections strengthen or weaken gedatolisib's commercial case; any efficacy/safety downgrades could affect Celc

Jun 4, 2026

Celcuity Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research